Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Endo up for auction this summer ...

<< Previous

Bullboard Posts

Next >>

Post by MrMugsyon Apr 28, 2023 11:45pm

241 Views

Post# 35420517

Endo up for auction this summer ...

Malvern-based Endo International is officially up for bidding. A U.S. Bankruptcy Court has approved the auction, and bidding procedures can begin at $6 billion, writes John George for the Philadelphia Business Journal.

The sale hearing for this year is set for Aug. 31, in New York City. Bidders have a deadline to submit their interest by June 13.

But ...

All 2,861 employees of Endo International must also be offered employment as part of the agreement. According to the pharmaceutical company.

Wonder if that hinders any kind of potential deal.

Interesting.